Medicine Press release



Universities and DENSO Develop Biosensor to Detect SARS-CoV-2 and Accelerate Development for Practical Application
Oct 21, 2021 15:41 JST
Tokai University, Toyohashi University of Technology, Chubu University, and DENSO Corporation have been developing testing equipment to detect SARS-CoV-2 with support from the Japan Agency for Medical Research and Development (AMED).
More info..


Universities and DENSO Develop Biosensor to Detect SARS-CoV-2 and Accelerate Development for Practical Application
Oct 21, 2021 15:41 JST
Tokai University, Toyohashi University of Technology, Chubu University, and DENSO Corporation have been developing testing equipment to detect SARS-CoV-2 with support from the Japan Agency for Medical Research and Development (AMED).
More info..


Hitachi, Tohoku University and Kyoto University Become World's First to Establish Technology for Highly Efficient, High-quality Production of Actinium-225, a Material Required for Internal Radiation Therapy Called TAT
Oct 19, 2021 13:03 JST
Hitachi, Ltd. (TSE: 6501), Tohoku University and Kyoto University have become the world's first (1) to establish technology for the highly efficient and high-quality production of actinium-225 (225Ac), a substance required for a form of radiation therapy known as targeted alpha therapy (TAT).
More info..


Hitachi, Tohoku University and Kyoto University Become World's First to Establish Technology for Highly Efficient, High-quality Production of Actinium-225, a Material Required for Internal Radiation Therapy Called TAT
Oct 19, 2021 13:03 JST
Hitachi, Ltd. (TSE: 6501), Tohoku University and Kyoto University have become the world's first (1) to establish technology for the highly efficient and high-quality production of actinium-225 (225Ac), a substance required for a form of radiation therapy known as targeted alpha therapy (TAT).
More info..


Fujitsu and Aichi Cancer Center Develop AI System to Offer Patients Personalized Cancer Treatment
Oct 19, 2021 09:28 JST
Aichi Cancer Center and Fujitsu Limited today announced the development of an AI solution able to select effective medical treatment from a wide range of drugs based on patients' individual cancer types and various genomic variants.
More info..


Eisai and Merck & Co., Inc. (Kenilworth, N.J.) Receive Positive EU CHMP Opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Two Different Types of Cancer
Oct 18, 2021 08:00 JST
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted positive opinions recommending approval of the combination of LENVIMA (marketed as Kisplyx in the European Union [EU].
More info..


Fujitsu and University of Tokyo Hospital Embark on Joint Research into AI to Aid the Fight Against Heart Disease
Oct 11, 2021 09:29 JST
Fujitsu Limited today announced that it has started joint clinical research with the University of Tokyo Hospital to verify the effectiveness of artificial intelligence technology to estimate abnormal heart movements based on electrocardiogram data.
More info..


Fujitsu AI Technology Recommends Exercises Customized to Users' Needs in New Trial
Oct 08, 2021 10:29 JST
Fujitsu announced the development of a prototype health enhancement solution based on its proprietary AI-powered 3D sensing technology.
More info..


Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway
Sep 28, 2021 10:37 JST
Eisai Co., Ltd. and Biogen Inc. today announced that Eisai has initiated a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company's investigational anti-amyloid beta (Abeta) protofibril antibody, for the treatment of early Alzheimer's disease (early AD).
More info..


Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
Sep 27, 2021 13:50 JST
AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA.
More info..